Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.52 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.38 |
| ▸ | FEN1 | P39748 | 8/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799212 | 0.78 | P2RX7 (0.59) | P2RX7ALOX5APALOX5FEN1NPC1 | |
| SCHEMBL5799218 | 0.77 | ALOX5AP (0.43) | P2RX7ALOX5APALOX5FEN1CYP3A4 | |
| SCHEMBL3346686 | 0.75 | P2RX7 (0.57) | P2RX7ALOX5APALOX5FEN1NPC1 | |
| SCHEMBL3342192 | 0.74 | ALPL (0.49) | P2RX7ALOX5APALOX5FEN1NPC1 | |
| SCHEMBL4469109 | 0.72 | P2RX7 (0.54) | P2RX7ALOX5APALOX5FEN1 | |
| SCHEMBL4460885 | 0.69 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL4469104 | 0.67 | ALOX5AP (0.39) | P2RX7ALOX5APALOX5FEN1CYP3A4 | |
| SCHEMBL4471895 | 0.65 | P2RX7 (0.57) | P2RX7NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL14966653 | 0.64 | P2RX7 (0.64) | P2RX7NPC1RAB9ASMN1; SMN2PRMT5 | |
| SCHEMBL4460890 | 0.62 | P2RX7 (0.58) | P2RX7ALOX5APALOX5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1837330-A1 | Benzamide inhibitors of the P2X7 receptor | Pfizer Products Inc. (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | PFIZER INC. | 2007-06-21 | — | — | US | claimed |
| EP-1837330-B1 | Benzamide inhibitors of the P2X7 receptor | PFIZER PROD INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7553972-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1837330-A1 | Benzamide inhibitors of the P2X7 receptor | Pfizer Products Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | PFIZER INC. | 2007-06-21 | — | — | US | disclosed |
| US-7186742-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER INC (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1626962-B1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | PFIZER PROD INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050009900-A1 | Benzamide inhibitors of the P2X7 receptor | ZOETIS LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885ALOX5AP 2972/4885ALOX5 2240/4885 |
| US-20050009900-A1 | Benzamide inhibitors of the P2X7 receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885ALOX5AP 2972/4885ALOX5 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.